Randall Bateman with DIAN-Tu participant (IMAGE) Washington University School of Medicine Caption Trial participant Rachel Habiger meets in 2018 with Randall J. Bateman, MD, the director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University School of Medicine in St. Louis. The DIAN-TU has announced that it will be targeting two key Alzheimer’s proteins — amyloid and tau — as part of its Tau Next Generation Alzheimer’s prevention trial. Credit Matt Miller/Washington University Usage Restrictions This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia-use/ for more information. License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.